About Jagsonpal
Jagsonpal is a company based in Delhi (India) founded in 1964. The company has 1,410 employees as of March 31, 2024. Jagsonpal has completed 2 acquisitions, including Aequitas Healthcare and Yash Pharma. Jagsonpal operates in a competitive market with competitors including Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
- Headquarter Delhi, India
- Employees 1410 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Jagsonpal Pharmaceuticals Ltd.
-
Annual Revenue
$31.49 M (USD)28.76as on Mar 31, 2025
-
Net Profit
$6.48 M (USD)146.45as on Mar 31, 2025
-
EBITDA
$6.05 M (USD)118.18as on Mar 31, 2025
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
1410
as on Mar 31, 2024
-
Investments & Acquisitions
Aequitas Healthcare
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Jagsonpal
Jagsonpal is a publicly listed company on the NSE with ticker symbol JAGSNPHARM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Jagsonpal
Unlock access to complete
Unlock access to complete
Funding Insights of Jagsonpal
Detailed funding history for Jagsonpal
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Jagsonpal
Jagsonpal has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Aequitas Healthcare and Yash Pharma.
Investment portfolio details for Jagsonpal
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Distributor of medical products
|
Locked | Locked | 2017 | Locked | |
|
Architect providing design and construction services for residential projects
|
Locked | Locked | 1972 | Locked |
Complete acquisition details for Jagsonpal
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Jagsonpal
Detailed financials for Jagsonpal
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Jagsonpal Comparisons
Peer comparison for Jagsonpal
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Jagsonpal
Jagsonpal operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Almac Group, Indoco Remedies, Concord Biotech, BDR Pharmaceuticals Internationals and Aurobindo Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Integrated CDMO services for biopharma R&D and manufacturing are offered.
|
|
| Locked | Locked | Locked |
APIs manufacturing and formulation services are provided in therapeutic segments.
|
|
| Locked | Locked | Locked |
APIs and enzymes are manufactured through fermentation by the CDMO.
|
|
| Locked | Locked | Locked |
APIs and finished products are developed and manufactured.
|
|
| Locked | Locked | Locked |
Generic biocatalytic solutions are provided for pharmaceutical applications.
|
|
| Locked | Locked | Locked |
APIs and peptides are developed and manufactured by Asymchem.
|
Detailed competitors of Jagsonpal
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Jagsonpal
Complete news archive for Jagsonpal
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jagsonpal
Jagsonpal was founded in 1964.
Jagsonpal is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.
Parveen Kaushal is the current CEO of Jagsonpal.
As of Mar 31, 2024, the latest employee count at Jagsonpal is 1,410.
Annual revenue of Jagsonpal is $31.49M as on Mar 31, 2025.
Jagsonpal was established in 1964 as a pharmaceutical entity focused on bulk drugs and finished formulations. A portfolio of 9 active pharmaceutical ingredients and over 200 formulation products is maintained. Operations span 13 countries across three continents, in addition to India. Contract manufacturing services are primarily provided to other pharmaceutical firms. The company is headquartered in Delhi, India.
Jagsonpal's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group.
Yes, Jagsonpal is publicly traded on NSE under the ticker symbol JAGSNPHARM.
Jagsonpal has made 2 acquisitions, including Aequitas Healthcare, and Yash Pharma.
The ticker symbol of Jagsonpal is JAGSNPHARM on NSE.